Receptor News and Research

RSS

Structured support may slow weight regain after stopping GLP-1 drugs

Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference, and other factors-commonly leading to rapid weight regain.

7 Oct 2026

UCLA researcher wins the 2026 Albany Prize for revolutionary cancer therapy discoveries

Dr. Dennis Slamon, a pioneering oncologist and researcher at the UCLA Health Jonsson Comprehensive Cancer Center, has been awarded the 2026 Albany Prize for discoveries that transformed the understanding and treatment of cancer.

6 Oct 2026

Managing misfolded proteins to prevent Parkinson’s disease

The protein alpha-synuclein is abundant in healthy brains and plays an important role in enabling communication between nerve cells. However, under certain conditions, misfolded alpha-synuclein proteins can accumulate into toxic clumps inside neurons

6 Oct 2026

Younger postmenopausal women may not get enough calcium

A small Italian study examined whether women facing heightened bone-loss risks are getting enough calcium from their diets, with particular attention to breast cancer patients receiving endocrine therapy.

6 Oct 2026

Phase III trial tests MRD-guided treatment for patients with ER-positive/HER2-negative breast cancer

Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer.

5 Oct 2026

Lipid signaling pathway helps cells survive bacterial toxin damage

Epithelial cells form the body's frontline barriers, helping keep microbes, toxins, and other harmful substances out.

5 Oct 2026

New BCR analysis method tracks immune recovery after stem cell transplantation

A research team led by Associate Professor Yohei Funakoshi, Associate Professor Kimikazu Yakushijin, and Professor Hironobu Minami of the Division of Medical Oncology/Hematology at Kobe University Hospital, together with Associate Professor Goh Ohji of the Division of Infectious Disease Therapeutics and Takaji Matsutani of Anymics Inc., has developed the pGen-SHM plot.

5 Oct 2026

Existing drug could target neuroinflammation in Alzheimer's patients

Inflammatory conditions in the brain, including traumatic brain injury and degenerative diseases like Alzheimer's could be targeted with an existing drug thanks to new research that shows it can work in brain cells.

5 Oct 2026

Enlicitide offers oral treatment option for patients avoiding cholesterol injections

In 2015, a new class of cholesterol-lowering injectable drugs called PCSK9-inhibitors was approved by the Food and Drug Administration (FDA) as a result of clinical research led by UT Southwestern.

5 Oct 2026

Dr. GPCR and Eurofins Discovery join forces to advance GPCR drug discovery

Dr. GPCR, the global knowledge hub for G protein-coupled receptor (GPCR) research and education, today announced a strategic partnership with Eurofins Discovery, the drug discovery services side of the same group behind the Eurofins DiscoverX products many in the community already know.

From Eurofins Discovery 5 Oct 2026

Tirzepatide cuts fat mass by 35% while preserving skeletal muscle

Tirzepatide cuts body fat while preserving skeletal muscle in real-world study

2 Oct 2026

Could the gut be priming the body for a more severe stroke?

Gut bacteria may prime immune cells to worsen stroke damage

2 Oct 2026

COVID-19 immunity shows cross-reactivity against related bat coronaviruses

People who recovered from COVID-19 infection or were vaccinated against SARS-CoV-2 are more likely to have immunity to other closely related bat coronaviruses that could have the potential to threaten future human health.

1 Oct 2026

Postpartum GLP-1 prescriptions rise sharply among U.S. women

More U.S. women are being prescribed GLP-1 medications after giving birth, particularly those diagnosed with diabetes, according to new research from the USC Schaeffer Center for Health Policy & Economics.

1 Oct 2026

New study reveals how VEGF-C amplifies lymphangiogenic signaling

Lymphatic vessels act as the body's "drainage system," collecting excess fluid from tissues. When lymphatic drainage is impaired because lymphatic vessels are underdeveloped, damaged, or dysfunctional, lymphedema can develop, causing swelling, particularly in the arms and legs.

1 Oct 2026

CBL-514 injection reduces visceral and subcutaneous fat in trials

Details of a new injection that targets fat cells will be released at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

1 Oct 2026

Synthetic protein targets TLR4 membrane region to reduce inflammation

To sense their environment and respond accordingly, cells enlist membrane proteins as communication hubs, receiving molecular messages from outside and triggering responses inside.

1 Oct 2026

Spatial mapping reveals macrophage niches linked to severe COVID-19 lung injury

Researchers at the University of Liège have used imaging-based spatial single-cell transcriptomics to map the cellular organization of lungs from people who died with severe COVID-19.

1 Oct 2026

Gut bacterial metabolite worsens brain damage after stroke, study finds

Researchers at LMU have discovered how a metabolite produced by gut bacteria can influence brain damage after stroke.

1 Oct 2026

Trevogrumab cuts semaglutide-induced lean mass loss by half, study shows

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and in press with The Lancet shows that using the trevogrumab to inhibit myostatin, a protein that negatively regulates muscle mass, can reduce lean mass loss during treatment with semaglutide by 50% compared with semaglutide and placebo.

1 Oct 2026